思创医惠(300078) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was CNY 167,667,885.38, a decrease of 29.55% compared to the same period last year[2] - Net profit attributable to shareholders was a loss of CNY 60,795,814.91, down 341.07% year-on-year[2] - Net profit excluding non-recurring items was a loss of CNY 62,808,853.52, an increase of 37.70% compared to the previous year[2] - Total operating revenue for Q3 2024 was CNY 564,563,042.63, a decrease of 29.6% compared to CNY 801,288,958.50 in the same period last year[17] - Net loss for Q3 2024 was CNY 285,718,834.44, compared to a net loss of CNY 112,349,718.70 in Q3 2023[18] - The total comprehensive income attributable to the parent company for Q3 2024 was -286,783,013.41 CNY, compared to -102,310,659.77 CNY in Q3 2023, indicating a significant decline[19] - The basic and diluted earnings per share for Q3 2024 were both -0.31 CNY, compared to -0.14 CNY in the same period last year[19] Assets and Liabilities - Total assets at the end of Q3 2024 were CNY 2,396,805,190.46, a decrease of 7.54% from the end of the previous year[2] - The company's total assets decreased to CNY 2,396,805,190.46 from CNY 2,592,337,624.35, reflecting a decline of 7.5%[16] - Total liabilities decreased to CNY 1,791,406,609.12 from CNY 2,084,592,658.95, a reduction of 14.1%[16] - The company’s long-term borrowings were CNY 263,008,341.71, slightly down from CNY 264,032,397.15 year-over-year[16] Shareholder Information - Shareholders' equity attributable to the parent company increased to CNY 592,144,386.55, up 19.62% year-on-year[2] - The total number of common shareholders at the end of the reporting period is 45,388, with the top 10 shareholders holding 59.02% of the shares[6] - The largest shareholder, Cangnan Sijia Intelligent Partnership, holds 6.21% of the shares, totaling 63,890,185 shares[6] - The company has a stock repurchase account holding 7,220,000 shares, representing 0.70% of the total share capital as of September 30, 2024[7] - The total number of restricted shares at the beginning of the period was 27,451,734, with 9,104,726 shares released during the period[8] - The number of restricted shares held by Zhang Lizhong decreased from 18,450,902 to 13,838,176 after the release of 4,612,726 shares[8] - The company has 4,505,082 shares under lock-up due to pre-IPO restrictions, which will be released at a rate of 25% annually[8] - The company’s shareholder, Fang Zhenchun, holds a total of 23,546,600 shares, with 16,648,000 shares held through a margin trading account[7] - The total number of shares held by the top 10 unrestricted shareholders is 63,890,185, with significant holdings from Cangnan Sijia and Yunhai Chain Holdings[6] - The company’s stock structure indicates a significant concentration of ownership among a few key shareholders, which may impact governance and decision-making[6] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 1,274,545.97, an increase of 112.64% compared to the same period last year[5] - Cash inflows from operating activities totaled 752,362,326.88 CNY, down from 979,245,972.75 CNY in Q3 2023, reflecting a decrease of approximately 23.1%[21] - The net cash flow from operating activities was 1,274,545.97 CNY, a recovery from a negative cash flow of -10,082,365.62 CNY in the previous year[21] - Cash outflows from investing activities were 596,355,131.60 CNY, compared to 917,135,020.31 CNY in Q3 2023, showing a reduction of about 35%[21] - The net cash flow from investing activities increased to 470,688,133.32 CNY, up from 299,422,700.21 CNY in the previous year[21] - Cash inflows from financing activities were 250,500,000.00 CNY, significantly lower than 1,234,764,000.00 CNY in Q3 2023, indicating a decrease of approximately 79.8%[22] - The net cash flow from financing activities was -476,415,935.60 CNY, worsening from -178,831,241.90 CNY in the same period last year[22] - The cash and cash equivalents at the end of Q3 2024 were 351,567,537.33 CNY, down from 546,990,595.92 CNY at the end of Q3 2023[22] Impairments and Adjustments - The company reported a significant decrease in goodwill by 86.29% due to impairment provisions[5] - The company’s goodwill stood at CNY 9,463,602.27, compared to CNY 69,042,195.24 in the previous year, indicating a substantial decrease[16] - The company reported a significant increase in credit impairment losses, totaling CNY 37,260,278.58, compared to CNY 52,173,135.83 in the previous year[18] - The company adjusted the conversion price of its convertible bonds to RMB 2.38 per share, effective from July 16, 2024[11] - In Q3 2024, the company reduced its convertible bonds by 2,930,983 units, resulting in a total of 123,149,525 shares converted[11] Other Financial Metrics - Total operating costs for Q3 2024 were CNY 747,741,398.44, down 16.3% from CNY 893,686,090.35 year-over-year[17] - Research and development expenses for Q3 2024 were CNY 86,530,617.16, down 27.5% from CNY 119,292,138.15 in the previous year[17] - The company reported a decrease in accounts receivable from RMB 554 million to RMB 431.9 million during the period[14] - The company’s inventory increased from RMB 217.2 million to RMB 221.6 million[14] - The company’s long-term equity investments decreased from RMB 141.1 million to RMB 138.9 million[14]